中國生物製藥(01177.HK):與友芝友生物簽署獨家許可與合作協議
格隆匯10月8日丨中國生物製藥(01177.HK)發佈公吿,公司附屬公司正大天晴藥業集團股份有限公司(“正大天晴”)與武漢友芝友生物製藥股份有限公司(“友芝友生物”)簽署獨家許可與合作協議,據此,正大天晴獲得友芝友生物研發的M701在中國大陸地區的開發、註冊、生產和商業化的獨家、可分許可的許可。
正大天晴將根據研發進展情況,就許可產品向友芝友生物支付約3.15億元人民幣的首付款及研發里程碑款項,並支付最高不超過7億元人民幣的銷售里程碑款項,同時按年淨銷售額的個位數至低雙位數百分比向友芝友生物支付分層特權使用費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.